You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for GIT 27
GIT 27 is an orally active immunomodulatory agent that primarily targets macrophages. Inhibits TNF-α secretion via interference of macrophage toll-like receptor (TLR) 4 and TLR 2/6 signaling pathway. Also reduces the secretion of pro-inflammatory cytokines IL1-β, IL-10 and IFN-γ. Antidiabetogenic; prevents IL-β and IFN-γ-induced pancreatic islet cell death in vitro.
Compound Libraries for GIT 27
Technical Data for GIT 27
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for GIT 27
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for GIT 27
The following data is based on the product molecular weight 205.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.87 mL||24.37 mL||48.73 mL|
|5 mM||0.97 mL||4.87 mL||9.75 mL|
|10 mM||0.49 mL||2.44 mL||4.87 mL|
|50 mM||0.1 mL||0.49 mL||0.97 mL|
References for GIT 27
References are publications that support the biological activity of the product.
Stosic-Grujicic et al (2007) A potent immunomodulatory compound (S,R)-3-phenyl-4,5-dihydro-5-isoxasoleacetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of stre J.Pharmacol.Exp.Ther. 320 1038 PMID: 17148780
Stojanovic et al (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin.Immunol. 123 311 PMID: 17449326
Mangano et al (2008) In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. Eur.J.Pharmacol. 586 313 PMID: 18374912
If you know of a relevant reference for GIT 27, please let us know.
Keywords: GIT 27, GIT 27 supplier, Interfers, TLR4, TLR2/6, signalling, Immunomodulators, reduces, production, pro-inflammatory, cytokines, Toll-like, Receptors, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, GI, 3270, Tocris Bioscience
1 Citation for GIT 27
Citations are publications that use Tocris products. Selected citations for GIT 27 include:
Saurus et al (2015) Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis 6 e1752 PMID: 25950482
Do you know of a great paper that uses GIT 27 from Tocris? Please let us know.
Reviews for GIT 27
There are currently no reviews for this product. Be the first to review GIT 27 and earn rewards!
Have you used GIT 27?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.